Cantor Fitzgerald lowered the firm’s price target on Jazz Pharmaceuticals to $180 from $210 and keeps an Overweight rating on the shares. The firm is positive on the progress Jazz made this quarter, highlighted by good execution across its commercial portfolio, with all three key growth- driving products achieving y/y double-digit growth, but the firm’s new valuation methodolgy includes a higher cost of capital assumption given the current rate environment, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $217 from $204 at BofA
- Jazz Pharmaceuticals sees FY23 adjusted EPS $18.15-$19.00, consensus $17.48
- Jazz Pharmaceuticals resumed share repurchases in Q2
- Jazz Pharmaceuticals reports Q2 adjusted EPS $4.51, consensus $4.42
- Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance